Eyenovia, Inc. is a high-risk pharmaceutical company based in the United States. With an ESG score of 33.4, Eyenovia is focused on developing innovative ophthalmic therapies through its proprietary MAP platform technology. The company's Opejet delivery system aims to revolutionize the way eye treatments are administered, offering improved safety, patient compliance, and success rates. Eyenovia is paving the way for the next generation of smart ophthalmic treatments by targeting new indications and combinations.